MX2022002687A - Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso. - Google Patents

Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso.

Info

Publication number
MX2022002687A
MX2022002687A MX2022002687A MX2022002687A MX2022002687A MX 2022002687 A MX2022002687 A MX 2022002687A MX 2022002687 A MX2022002687 A MX 2022002687A MX 2022002687 A MX2022002687 A MX 2022002687A MX 2022002687 A MX2022002687 A MX 2022002687A
Authority
MX
Mexico
Prior art keywords
methods
fatty acids
polyunsaturated fatty
hydroxylated
elovanoid
Prior art date
Application number
MX2022002687A
Other languages
English (en)
Spanish (es)
Inventor
Ricardo Palacios Pelaez
Nicolas G Bazan
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of MX2022002687A publication Critical patent/MX2022002687A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022002687A 2019-09-04 2020-09-04 Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso. MX2022002687A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962895737P 2019-09-04 2019-09-04
US201962923770P 2019-10-21 2019-10-21
US201962924359P 2019-10-22 2019-10-22
US202062964995P 2020-01-23 2020-01-23
PCT/US2020/049541 WO2021046448A1 (en) 2019-09-04 2020-09-04 Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Publications (1)

Publication Number Publication Date
MX2022002687A true MX2022002687A (es) 2022-06-16

Family

ID=74853054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002687A MX2022002687A (es) 2019-09-04 2020-09-04 Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso.

Country Status (9)

Country Link
US (1) US20220339134A1 (enExample)
EP (1) EP4025201A4 (enExample)
JP (2) JP2022547080A (enExample)
CN (1) CN114650814A (enExample)
AU (1) AU2020343029A1 (enExample)
BR (1) BR112022003985A2 (enExample)
CA (1) CA3153088A1 (enExample)
MX (1) MX2022002687A (enExample)
WO (1) WO2021046448A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056311A1 (en) * 2020-09-10 2022-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN118524834A (zh) * 2021-12-03 2024-08-20 株式会社日水 氧化应激缓和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037180A1 (en) * 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Anionic oligosaccharide conjugates
US20130190399A1 (en) * 2009-10-31 2013-07-25 Martek Biosciences Corporation Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
WO2016130522A1 (en) * 2015-02-09 2016-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
US20170014365A1 (en) * 2015-07-14 2017-01-19 The Board Of Regents Of The University Of Oklahoma Compositions Containing Very Long Chain Saturated Fatty Acids and Methods of Use
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
CA3056882A1 (en) * 2017-03-20 2018-09-27 University Of Southern California Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Also Published As

Publication number Publication date
JP2025143368A (ja) 2025-10-01
CN114650814A (zh) 2022-06-21
EP4025201A4 (en) 2023-08-30
JP2022547080A (ja) 2022-11-10
BR112022003985A2 (pt) 2022-05-24
EP4025201A1 (en) 2022-07-13
US20220339134A1 (en) 2022-10-27
CA3153088A1 (en) 2021-03-11
WO2021046448A1 (en) 2021-03-11
AU2020343029A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CO2021014835A2 (es) Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso
PE20180456A1 (es) Acidos grasos poliinsaturados de cadena muy larga a partir de aceites naturales
CO2021008018A2 (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
CL2021001407A1 (es) Acidos grasos de cadena muy larga
CO6351713A2 (es) Composición nutricional para promover desarrollo y crecimiento sanos
MX2018006241A (es) Produccion de derivados de olefina grasa via metatesis de olefina.
MX386098B (es) Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas.
AR073855A1 (es) Utilizacion de desaturasas de acidos grasos de hemiselmis spp.
CL2019003072A1 (es) Composiciones nutricionales y farmacéuticas encapsuladas.
MX2021009825A (es) Suplemento alimenticio.
CO2021000418A2 (es) Composiciones de ácidos grasos poliinsaturados enriquecidos con ala
AR113673A1 (es) Composiciones de ácidos grasos poliinsaturados enriquecidos con dha
BR112022003985A2 (pt) Ácidos graxos poliinsaturados de cadeia muito longa, derivados elovanoides hidroxilados e métodos de uso
CO2026001593A2 (es) Composiciones de recubrimiento que incluyen alcoholes grasos
CL2021001428A1 (es) Proceso para un fideo instantáneo frito en aceite
MX368689B (es) Derivados de citocromo p450 (cyp)-eicosanoide novedosos.
AR113710A1 (es) Composiciones de ácidos grasos poliinsaturados enriquecidos con dha
MA39445A1 (fr) Sélection, production et alimentation d'algues entières comme complément alimentaire pour le bétail et les bisons pour produire de la viande à teneur élevée en oméga 3's pour la santé humaine
AR101724A1 (es) COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA
CL2023001249A1 (es) Cepa mutante del alga nannochloropsis, método para obtenerla y usos de sus productos.
EA202091316A1 (ru) Обогащенный олеиновой кислотой растительный организм, имеющий генетически модифицированный fad2, и способ его получения
MX2021003040A (es) Composiciones de alimentos animales y usos de las mismas.
EP3793972A4 (en) TOTAL SYNTHESIS OF PROSTAGLANDIN-J NATURAL PRODUCTS BY STEREOSELECTIVE METATHESIS
PH12020550124B1 (en) Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
BR112022006574A2 (pt) Novos aditivos de ração de vitaminas lipossolúveis